The Software Architecture and development approach for the ASTRI Mini-Array gamma-ray air-Cherenkov experiment at the Observatorio del Teide

The ASTRI Mini-Array is an international collaboration led by the Italian National Institute for Astrophysics (INAF) and devoted to the imaging of atmospheric Cherenkov light for very-high gamma-ray astronomy. The project is deploying an array of 9 telescopes sensitive above 1 TeV. In this contribution, we present the architecture of the software that covers the entire life cycle of the observatory, from scheduling to remote operations and data dissemination. The high-speed networking connection available between the observatory site, at the Canary Islands, and the Data Center in Rome allows for ready data availability for stereo triggering and data processing

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

A closed loop transmitting power self-calibration scheme for energy efficient WiNoC architectures

In a wireless Network-on-Chip (WiNoC) the radio transceiver accounts for a significant fraction of the total communication energy. Recently, a configurable transceiver architecture able to regulate its transmitting power based on the location of the destination node has been proposed. Unfortunately, the use of such transceiver requires a costly, time consuming and complex characterization phase performed at design time and mainly based on the use of field solver simulators whose accuracy has not yet been proved in the context of integrated on-chip antennas. In this paper we present a closed loop transmitting power self-calibration mechanism which allows to determine on-line the optimal transmitting power for each transmitting and receiving pair in a WiNoC. The proposed mechanism is general and can be applied to any WiNoC architecture with a low overhead in terms of silicon area. Its application to three well known WiNoC architectures shows its effectiveness in drastically reducing the overall communication energy (up to 50%) with a limited impact on performance

TRAJECTORY CLASSIFICATION OF INTEGRATED HAMILTONIAN SYSTEMS WITH TWO DEGREES OF FREEDOM

The theory construction of the trajectory classification of inregrated hamiltonian systems with two degrees of freedom is the aim of the paper as well as the investigation of trajectory invariants; the development of applications to mechanics. As a result the theory of the continuous and smooth trajectory classification of integrated hamiltonian systems with two degrees of freedom has been constructed. New trajectory invariants of these systems have been discovered. Methods for their calculation have been developed. The paper results may find their field of application in geometry and topology of hamiltonian systems, symplex geometryAvailable from VNTIC / VNTIC - Scientific & Technical Information Centre of RussiaSIGLERURussian Federatio

Monosegmental vs bisegmental pedicle fixation for the treatment of thoracolumbar spine fractures

The anatomy and biomechanics of the thoracolumbar spine place these segments at high risk of trauma injuries. Treatment options are either conservative or surgical, and there is a lack of consensus about the right indications. International scientific publications agree only on basic surgical principles: vertebral stability, deformity correction, protection of neurological structures and fast functional recovery. The most commonly used approach is the posterior approach, which allows the best management of most vertebral fracture patterns. The aim of this study was to compare clinical and radiological outcomes of monosegmental stabilisation with those of bisegmental stabilisation and fusion in the treatment of traumatic thoracolumbar spine fractures

Porcine Models in Spinal Research: Calibration and Comparative Finite Element Analysis of Various Configurations during Flexion–Extension

This study was conducted to develop and calibrate a detailed 3-dimensional finite element model of the porcine lumbar spine and to compare this model with various configurations in flexion and extension. Computed tomography scans obtained from the L4–L5 lumbar segment of a Landrace × Large White pig were used to generate a solid volume. The various passive components were characterized by using a step-by-step calibration procedure in which the material properties of the anatomic structures were modified to match the corresponding in vitro data set-points retrieved from the literature. The range of motion of the totally assembled intact model was assessed under a 10-Nm flexion–extension moment and compared with data from a bilateral complete and hemifacetectomy configuration. In addition, the results from our porcine model were compared with published data regarding range of motion in a human finite element model in order to predict the configuration of the porcine model that most closely represented the human spine. Both the intact and hemifacetectomy configurations of the porcine model were comparable to the human spine. However, qualitative analysis of the instantaneous axis of rotation revealed a dissimilarity between the intact porcine model and human spine behavior, indicating the hemifacetectomy configuration of the porcine model as the most appropriate for spinal instrumentation studies. The present 3-dimensional finite element porcine model offers an additional tool to improve understanding of the biomechanics of the porcine spine and to decrease the expense of spinal research

Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database

Objectives: To assess the predictive accuracy and the clinical value of a recent nomogram predicting cancer-specific mortality-free survival after surgery in pN1 prostate cancer patients through an external validation. Methods: We evaluated 518 prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection with evidence of nodal metastases at final pathology, at 10 tertiary centers. External validation was carried out using regression coefficients of the previously published nomogram. The performance characteristics of the model were assessed by quantifying predictive accuracy, according to the area under the curve in the receiver operating characteristic curve and model calibration. Furthermore, we systematically analyzed the specificity, sensitivity, positive predictive value and negative predictive value for each nomogram-derived probability cut-off. Finally, we implemented decision curve analysis, in order to quantify the nomogram's clinical value in routine practice. Results: External validation showed inferior predictive accuracy as referred to in the internal validation (65.8% vs 83.3%, respectively). The discrimination (area under the curve) of the multivariable model was 66.7% (95% CI 60.1-73.0%) by testing with receiver operating characteristic curve analysis. The calibration plot showed an overestimation throughout the range of predicted cancer-specific mortality-free survival rates probabilities. However, in decision curve analysis, the nomogram's use showed a net benefit when compared with the scenarios of treating all patients or none. Conclusions: In an external setting, the nomogram showed inferior predictive accuracy and suboptimal calibration characteristics as compared to that reported in the original population. However, decision curve analysis showed a clinical net benefit, suggesting a clinical implication to correctly manage pN1 prostate cancer patients after surgery

Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database

Objectives: To assess the predictive accuracy and the clinical value of a recent nomogram predicting cancer-specific mortality-free survival after surgery in pN1 prostate cancer patients through an external validation. Methods: We evaluated 518 prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection with evidence of nodal metastases at final pathology, at 10 tertiary centers. External validation was carried out using regression coefficients of the previously published nomogram. The performance characteristics of the model were assessed by quantifying predictive accuracy, according to the area under the curve in the receiver operating characteristic curve and model calibration. Furthermore, we systematically analyzed the specificity, sensitivity, positive predictive value and negative predictive value for each nomogram-derived probability cut-off. Finally, we implemented decision curve analysis, in order to quantify the nomogram's clinical value in routine practice. Results: External validation showed inferior predictive accuracy as referred to in the internal validation (65.8% vs 83.3%, respectively). The discrimination (area under the curve) of the multivariable model was 66.7% (95% CI 60.1-73.0%) by testing with receiver operating characteristic curve analysis. The calibration plot showed an overestimation throughout the range of predicted cancer-specific mortality-free survival rates probabilities. However, in decision curve analysis, the nomogram's use showed a net benefit when compared with the scenarios of treating all patients or none. Conclusions: In an external setting, the nomogram showed inferior predictive accuracy and suboptimal calibration characteristics as compared to that reported in the original population. However, decision curve analysis showed a clinical net benefit, suggesting a clinical implication to correctly manage pN1 prostate cancer patients after surgery

Extraits d'opéras / Rossini, Donizetti, Verdi... [et al.], comp. ; Roberta Peters, S ; orchestre et choeurs de l'Opéra de Rome ; Vincenzo Belleza, Jonel Perlea, dir.

Comprend : Le Barbier de Séville. Una voce poco fa / Rossini, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Luci de Lammermoor. Il dorce suono / Donizetti, comp. ; Roberta Peters, S ; choeurs et orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Luci de Lammermoor. Ardon gl'insensi / Donizetti, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Luci de Lammermoor. Spargi d'amaro pianto / Donizetti, comp. ; Roberta Peters, S ; choeurs et orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Rigoletto. Tutte le fest al tempio / Verdi, comp. ; Roberta Peters, S ; Vinvenzo Preziosa, B ; André Mineo, BAR ; orchestre de l'Opéra de Rome ; Jonel Perlea, dir. - Fra Diavolo. Non temete, Milord / Auber, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Fra Diavolo. Or son sola / Auber, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Rigoletto. Caro nome / Verdi, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Jonel Perlea, dir. - Lakme. Où va la jeune Hindoue ? / Delibes, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Lakme. Là-bas dans la forêt profonde / Delibes, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Don Pasquale. Quel guardo il cavaliere / Donizetti, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir. - Don Pasquale. So anch'io la virtu magica / Donizetti, comp. ; Roberta Peters, S ; orchestre de l'Opéra de Rome ; Vincenzo Bellezza, dir.BnF-Partenariats, Collection sonore - BelieveContient une table des matière